Designation of Nitisinone (Orfadin) as an orphan drug - A. Menarini Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 (TGA Act) is the foundational piece of legislation governing the regulation of therapeutic goods in Australia. Enacted in 1989, the TGA Act was introduced to address the need for a comprehensive regulatory framework that ensures the safety, quality, and efficacy of therapeutic goods available to the Australian public. The Act provides the Therapeutic Goods Administration (TGA) with the authority to regulate therapeutic goods, including medicines, medical devices, and blood products, to protect public health. The policy objective of the TGA Act is to ensure that therapeutic goods are of acceptable quality and do not pose unacceptable risks to users or the public. The Act is administered by the Parliament of Australia, with the TGA operating under the Department of Health. This particular designation, issued by Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990, identifies nitisinone (Orfadin) as an orphan drug for the treatment of patients with hereditary tyrosinaemia type 1. This designation recognises the rarity of the condition and the need for specialised treatments, providing a framework for the development and availability of orphan drugs in Australia. The sponsor for nitisinone (Orfadin) is A. Menarini Australia Pty Ltd, highlighting the collaborative effort between industry and regulatory bodies in addressing unmet medical needs.

Scope and Application

The Therapeutic Goods Act 1989 applies to the designation of certain therapeutic goods, including the designation of a drug as an orphan drug for specific medical conditions. The Act provides the framework for the regulation of therapeutic goods in Australia, including medicines, medical devices, and other related products. In this instance, nitisinone (Orfadin) has been designated as an orphan drug for the treatment of hereditary tyrosinaemia type 1 under the authority of the Therapeutic Goods Regulations 1990. The Act applies to the sponsor of the drug, in this case, A. Menarini Australia Pty Ltd, and to patients who will be treated with nitisinone (Orfadin) for the specified condition. The scope of the Act is limited to the Commonwealth jurisdiction, with the Therapeutic Goods Administration being the responsible regulatory body. The designation of nitisinone (Orfadin) as an orphan drug is specific to the treatment of hereditary tyrosinaemia type 1 and does not extend to other conditions or uses. The Act does not specify any exclusions or exemptions for this particular designation, and the application of the Act is not subject to any stated thresholds. The application of the Act may be extended or restricted through subordinate instruments, such as the Therapeutic Goods Regulations 1990, which provide further detail on the requirements and processes for the regulation of therapeutic goods in Australia.

Key Provisions

The main operative sections of this legislative instrument pertain to the designation of nitisinone (Orfadin) as an orphan drug for the treatment of hereditary tyrosinaemia type 1 (HT-1) (Section 1). This designation acknowledges the drug's importance in addressing a rare and severe genetic disorder. Specifically, Section 1 outlines the decision to designate nitisinone (Orfadin) as an orphan drug, effective from 31 August 2016, for use in capsules and oral liquid suspension form. The sponsor of this drug, A. Menarini Australia Pty Ltd, is identified in Section 1 as the entity responsible for the drug’s production and distribution under the Therapeutic Goods Act 1989. The Therapeutic Goods Act 1989 imposes certain obligations on the parties involved. The Therapeutic Goods Administration (TGA) has the responsibility to ensure that therapeutic goods, including orphan drugs, meet safety, quality, and efficacy standards. The sponsor, A. Menarini Australia Pty Ltd, must provide sufficient evidence and documentation to support the orphan drug designation. This includes demonstrating the rarity of the condition the drug is intended to treat and the drug’s potential to provide significant benefit to patients suffering from HT-1. Additionally, the sponsor must comply with all relevant regulatory requirements to maintain the drug’s status as an orphan drug. Breaching the obligations under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in significant consequences. Offences may include the unauthorised sale or supply of therapeutic goods, failure to comply with labelling requirements, or providing misleading information about a drug's safety or efficacy. The penalties for such breaches can vary, with potential civil penalties including fines and, in more severe cases, criminal penalties such as imprisonment. The exact penalties depend on the nature and severity of the offence, but the Therapeutic Goods Act 1989 provides for substantial fines and imprisonment terms for serious violations. For example, individuals and corporations can face fines of up to $2,200,000 and imprisonment for up to 10 years for certain offences. These stringent measures underscore the importance of compliance with the regulatory framework designed to protect public health.